Tomáš Büchler

Charles University — Czech Republic

Medicine · Health Sciences

34h-index5.7kcitations405works9.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(88), Colorectal Cancer Treatments and Studies(54), Multiple Myeloma Research and Treatments(46), Cancer Immunotherapy and Biomarkers(44), Cancer Genomics and Diagnostics(41)

Publications405 total

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Prostate Cancer and Prostatic Diseases·2026Open Access
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
The Lancet Oncology·2025· 1 cited
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab
Scientific Reports·2025Open Access
Cardiac metastasis of urothelial carcinoma mimicking ST-elevation myocardial infarction
Klinicka onkologie·2025Open Access
Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry
Cancer Medicine·2025Open Access
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Cancer Immunology Immunotherapy·2025Open Access
Second-line cabozantinib after failure of immune-based therapy in patients with metastatic renal cell carcinoma: Analysis of the RENIS II registry
European Urology Open Science·2025Open Access
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial
Annals of Oncology·2025· 2 citedOpen Access
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures
Annals of Medicine·2025Open Access
Risk of second primary malignancies after adjuvant chemotherapy for colon cancer
Cancer·2025Open Access
871eP Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS
Annals of Oncology·2025
WITHDRAWN: 2442P Doublet vs. Triplet therapy in high volume metastatic hormone-sensitive prostate cancer patients with bone metastases: Results from the ARON-3 study
Annals of Oncology·2025
2801O Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial
Annals of Oncology·2025
Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab
Clinical & Experimental Metastasis·2025· 1 citedOpen Access
64P PROMETCO: Real-world characteristics and safety outcomes of patients with metastatic colorectal cancer (mCRC) after two disease progressions, including patients with ECOG-PS >2
Annals of Oncology·2025Open Access
Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project
Clinical Genitourinary Cancer·2025
Risk factors and causes of early death among patients with germ cell testis tumors (GCTs): An international collaborative study supported by the Global Society of Rare Genitourinary Tumors.
Journal of Clinical Oncology·2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Cancer Immunology Immunotherapy·2025· 1 citedOpen Access
Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective
Targeted Oncology·2025Open Access
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
page 1 of 21Next →

Frequent Co-authors

Bohuslav Melichar(12), Pavel Vodička(11), Veronika Vymetálková(10), Jiří Vorlíček(8), Ondřej Fiala(8), Camillo Porta(7), Alexandr Poprach(7), Barbara Pardini(7), Alessio Naccarati(7), Roman Hájek(7), Miroslav Levý(7), Toni K. Choueiri(6), Ugo De Giorgi(6), Ladislav Dušek(6), Rostislav Vyzula(6), Ľudmila Vodičková(6), Kateřina Jirásková(6), Václav Liška(6), Cornelia Di Gaetano(6), Veronika Veškrňová(5)